Magnetic Beads Make Chromatin Immunoprecipitation Faster and Easier

Total Page:16

File Type:pdf, Size:1020Kb

Load more

THE NEWSLETTER OF ACTIVE MOTIF — November 2006 • volume 7 • number 4 New: Magnetic Beads Make Chromatin INSIDE THIS ISSUE Immunoprecipitation Faster and Easier 2 ELISA for Quantifi cation of Activated Ras GTPase Active Motif’s new ChIP-IT™ Express Kits use protein G-coated magnetic beads Simplify Co-Immunoprecipitation instead of traditional agarose beads to make chromatin immunoprecipitation 3 (ChIP) simpler and faster than ever before. These innovative beads have made 4 Investigate SUMOylation with Simple, Effi cient SUMOlink™ it possible to simplify and streamline the protocol, optimize buffers and 5 New: Study Your Choice of reduce or eliminate several time- and labor-intensive steps. The result is that Target in Any Cell Signaling ChIP-IT Express enables you to perform ChIP in a single day. Pathway 7 TransAM™: The Simple Way to Assay Transcription Factor New technique for speed and success ously elute your DNA from the beads Activation The new components and protocol while reversing the cross-links. These of ChIP-IT Express make it faster and simple protocol changes give you results 8 Simplifi ed Analysis of easier than any other ChIP procedure. quickly and easily while offering the DNA Methylation The kits include all buffers, reagents freedom to simultaneously perform and components required to shear 5 multiple ChIP assays: now you can even samples of chromatin, using your choice perform ChIP in PCR tubes with a multi- of sonication or enzymatic digestion, channel pipettor (Figure 1). then perform 25 ChIP reactions. We’ve even included a strong bar magnet. The The power of magnetic beads protein G-coated magnetic beads, pro- With ChIP-IT Express Kits, ChIP can vided ready-to-use, have a high binding be performed in the included Eppen- capacity for IgG. This enables them to dorf tubes or in 8-well PCR strips. PCR be used in small volumes, which reduces strips make it convenient to process non-specifi c binding. This improved larger numbers of samples. The protein specifi city enables the number and G-coated magnetic beads pellet in length of washing steps to be reduced. It seconds, much faster than centrifuging is not even necessary to block the beads agarose beads. An added advantage is or pre-clear the chromatin. that magnetic beads pellet on the tube side instead of the bottom, even coming Optimized buffers eliminate steps completely out of the wash buffer. This Figure 1: Multiple-sample ChIP using ChIP-IT Express. Washing magnetic beads is fast and easy because the In addition to the magnetic beads and makes it easy to remove buffers without pellet forms against the side of the tube in seconds. bar magnet, ChIP-IT Express Kits contain disturbing the beads, which reduces This makes it possible to ChIP multiple samples in new buffers that eliminate the need for sample loss and helps ensure sample-to- 8-well PCR tubes using a multi-channel pipettor. DNA purifi cation, so you can simultane- sample consistency. continued on page 6 www.activemotif.com 1 Small GTPase Activation ELISA for Quantifi cation of Activated Ras GTPase Active Motif’s Ras GTPase Chemi ELISA Kit is the fi rst ELISA-based kit Ras ELISA advantages designed to detect and quantify activated Ras GTPase. The method offers • More sensitive – assay uses only 25 µg of extract, or 20-fold less several advantages over other commercially available kits, which require you than pull-down/Western methods to perform immunoprecipitation of Ras, followed by Western blotting. • Better results – quantitative data makes it easier to compare results In contrast, the Ras GTPase Chemi ELISA as a probe to isolate activated Ras. The • Less effort – no need to perform IP, uses Raf-RBD protein and antibodies in Ras ELISA Kit contains a Raf-RBD protein run gels or develop Western blots a 96-well format to capture and quan- fused to GST and a 96-well, glutathione- • Save time – results in < 5 hours tify the activated Ras in your sample. coated assay plate. GST-Raf-RBD is fi rst • Versatile – assay activated extracts This faster, more sensitive alternative incubated on the plate for one hour to from cells or tissue samples, or enables you to use less of your precious immobilize this capture protein. Addi- study recombinant Ras protein sample, yet still detect low-level events. tion of sample to the plate results in the In addition, because ELISAs provide more binding of activated Ras to the Raf-RBD. 800000 Unstimulated quantitative results than Westerns, the A primary antibody specifi c for Ras is EGF stimulated data generated is more meaningful. then added, followed by an HRP-conju- 600000 gated secondary antibody and develop- 400000 ed Ras Signal (RLU) The Ras GTPase Chemi ELISA method ing reagent (Figure 1). The plate is then at Activ 200000 Because activated Ras binds specifi cally read on a luminometer, which provides a 0 to the Ras-binding domain (RBD) of the sensitive, quantitative chemiluminescent 6.25 12.5 25 50 Raf effector protein, Raf-RBD is used readout of activated Ras (Figure 2). Cell extract (µg/well) Figure 2: Quantifi cation of activated Ras. Increasing amounts of whole-cell extract from HeLa cells that had been stimulated with 5 ng/ml EGF for 2 minutes “ELISAs are faster and more sensitive than other methods used to were assayed using the Ras GTPase Chemi ELISA Kit. study GTPase activation, and eliminate the need for IP, gels and blots.” Try the quantitative, sensitive assay The Ras GTPase Chemi ELISA Kit makes Add primary Add anti-IgG antibody HRP conjugate it fast and easy to detect and quantify 45 min activated Ras GTPase. The kit is ideal 45 min 45 min for the study of novel signaling path- Add cell Add developing extract to solution, then ways that activate Ras, as well as for plate quantify determining if a particular malignancy is related to inappropriately activated, oncogenic Ras. Please give us a call, re- turn the enclosed reply card or visit our website at www.activemotif.com/gtpase Cell extract containing activated GST-Raf-RBD for complete information, including Ras GTPase coated plate downloadable manuals. To get to the Figure 1: Flowchart of the Ras GTPase Chemi Kit. best Ras activation assay available, try Cell extract is added to a glutathione-coated plate that contains immobilized GST-Raf-RBD protein. Activated Ras in the the Ras GTPase Chemi ELISA Kit. extract binds to the Raf-RBD protein. Addition of primary & secondary antibodies and developing solution followed by reading on a luminometer enables sensitive quantification of activated Ras. Product Format Catalog No. Ras GTPase Chemi ELISA Kit 1 x 96-well plate 52097 2 Toll Free — 1 877 222 9543 November 2006 • volume 7 • number 4 Co-Immunoprecipitation Simplify Co-Immunoprecipitation Active Motif’s Nuclear Complex Co-IP Kit simplifi es co-immunoprecipitation studies of nuclear protein complexes by providing you with optimized reagents 250 for both nuclear extract preparation and immunoprecipitation. 1 2 3 The Nuclear Complex Co-IP’s extraction bound, interacting proteins. The complex Figure 1: Western blot analysis of the IP’d p33 subunit of the RNA pol II complex. process provides a simple and effective is then detected by Western blot using a HeLa cells were grown to confluence on 100 mm plates method to obtain and maintain protein second antibody targeted against one of and nuclear extracts were prepared using the kit’s complexes contained in nuclear compart- the bound, interacting proteins. However, extraction reagents. For IP experiments, the stringency of the IP High Buffer was increased by supplementing ments of the cell, specifi cally those previ- traditional methods for performing Co-IP with NaCl and Detergent. 100 µg of nuclear extract was ously bound to DNA, while the versatile are not optimal for studying complexes of used per IP reaction and incubated with either 2 µg p33 antibody or no antibody. Following the IP, Western Co-IP reagents offers you the fl exibility DNA-binding proteins as these complexes, blot analysis was performed using RNA pol II mouse to vary the stringency of the Co-IP buffer being fragile, are frequently disrupted mAb at 0.1 µg/ml followed by anti-mouse HRP at 1:1000. compositions. This improves your results during the extraction process. In addition, Detection of the p33/RNA pol II complex by the RNA pol II antibody (lane 3) demonstrates that the Co-IP and enables you to study tightly bound many protein complexes are altered by was successful in maintaining the protein complex. The or weak protein complexes with ease. the salt and detergent composition of the input HeLa extract (lane 1) was run as a control for the buffers used in the immunoprecipitation Western blot using 0.1 µg/ml RNA pol II. Co-Immunoprecipitation (Co-IP) is often process, which can complicate their Lane 1 Western blot control Lane 2 Negative Control (no antibody used in IP) used to fi nd and study protein/protein analysis. To overcome these problems, Lane 3 Co-IP: IP using p33/WB using RNA pol II interactions. In Co-IP, a fi rst antibody the Nuclear Complex Co-IP Kit extraction is used to immunoprecipitate a target reagents were designed to help maintain The Co-IP Kit also contains high and low antigen, which also co-precipitates any nuclear protein complexes. stringency IP buffers, as well as salt and detergent. Addition of salt and detergent is ideal for robust protein/protein inter- “The Nuclear Complex Co-IP Kit simplifi es co-immunoprecipitation of DNA- actions because it reduces background. binding proteins from cell and tissue samples by providing both extraction and However, as unstable protein complexes immunoprecipitation components that maintain nuclear protein complexes.” may not withstand high stringencies, this convenient kit format enables stringency to be modifi ed as required for each Cell nucleus containing the two Nuclear extraction Add antibody directed against Add antibody particular protein complex.
Recommended publications
  • Comparison of Immunohistochemistry with Immunoassay (ELISA

    Comparison of Immunohistochemistry with Immunoassay (ELISA

    British Journal of Cancer (1999) 79(9/10), 1534–1541 © 1999 Cancer Research Campaign Article no. bjoc.1998.0245 Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue CM Ferrier1, HH de Witte2, H Straatman3, DH van Tienoven2, WL van Geloof1, FJR Rietveld1, CGJ Sweep2, DJ Ruiter1 and GNP van Muijen1 Departments of 1Pathology, 2Chemical Endocrinology and 3Epidemiology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands Summary Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33 cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly, the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from different scoring classes.
  • Immunoassay - Elisa

    Immunoassay - Elisa

    IMMUNOASSAY - ELISA PHUBETH YA-UMPHAN National Institute of Health, Department of Medical Sciences 0bjective After this presentation, participants will be able to Explain how an ELISA test determines if a person has certain antigens or antibodies . Explain the process of conducting an ELISA test. Explain interactions that take place at the molecular level (inside the microtiter well) during an ELISA test. Outline - Principal of immunoassay - Classification of immunoassay Type of ELISA - ELISA ELISA Reagents General - Applications Principal of ELISA ELISA workflow What is immunoassay? Immunoassays are bioanalytical methods that use the specificity of an antigen-antibody reaction to detect and quantify target molecules in biological samples. Specific antigen-antibody recognition Principal of immunoassay • Immunoassays rely on the inherent ability of an antibody to bind to the specific structure of a molecule. • In addition to the binding of an antibody to its antigen, the other key feature of all immunoassays is a means to produce a measurable signal in response to the binding. Classification of Immunoassays Immunoassays can be classified in various ways. Unlabeled Labeled Competitive Homogeneous Noncompetitive Competitive Heterogeneous Noncompetitive https://www.sciencedirect.com/science/article/pii/S0075753508705618 Classification of Immunoassays • Unlabeled - Immunoprecipitation • Labeled Precipitation of large cross-linked Ag-Ab complexes can be visible to the naked eyes. - Fluoroimmnoassay (FIA) - Radioimmunoassay (RIA) - Enzyme Immunoassays (EIA) - Chemiluminescenceimmunoassay(CLIA) - Colloidal Gold Immunochromatographic Assay (ICA) https://www.creative-diagnostics.com/Immunoassay.htm Classification of Immunoassays • Homogeneous immunoassays Immunoassays that do not require separation of the bound Ag-Ab complex. (Does not require wash steps to separate reactants.) Example: Home pregnancy test. • Heterogeneous immunoassays Immunoassays that require separation of the bound Ag-Ab complex.
  • Laboratory Techniques Used for Immunological Laboratory Methods

    Laboratory Techniques Used for Immunological Laboratory Methods

    Laboratory techniques used for Immunological laboratory methods Dr. Tatiana Jones, MD, PhD NCC How to Make Serial Dilutions? Interpretation can be made differently depending on the nature of test. For example, if we need to figure out in what sample the concentration of the antibody or antigen is higher, we will go by TITER, which is the lowest serial dilution (let’s say that it is 1:32 in the picture on the left) that gives us positive result. This mean that even diluted 32 times sample is still capable of reacting. The other scenario when we are interpreting quantitative assays, such as ELISA. In this case we need to match results of our samples to known concentrations of STANDARD and MULTIPLY be our dilution factor. What is Antibody Titer? An antibody titer is a measurement of how much antibody an organism has produced that recognizes a particular antigen. Titer is expressed as the inverse of the greatest dilution that still gives a positive result. ELISA is a common means of determining antibody titers. How to Determine Antibody Titer? Where we can use Indirect Coombs test detects the presence of anti-Rh antibodies in blood serum. A patient might be reported to have an "indirect Antibody Titer? Coombs titer" of 16. This means that the patient's serum gives a positive indirect Coombs test at any dilution down to 1/16 (1 part serum to 15 parts diluent). At greater dilutions the indirect Coombs test is negative. If a few weeks later the same patient had an indirect Coombs titer of 32 (1/32 dilution which is 1 part serum to 31 parts diluent), this would mean that more anti-Rh antibody was made, since it took a greater dilution to eradicate the positive test.
  • An Enzyme-Linked Immunosorbent Assay (ELISA) for Pantothenate

    An Enzyme-Linked Immunosorbent Assay (ELISA) for Pantothenate

    Utah State University DigitalCommons@USU All Graduate Theses and Dissertations Graduate Studies 5-1981 An Enzyme-Linked Immunosorbent Assay (ELISA) for Pantothenate Allen H. Smith Utah State University Follow this and additional works at: https://digitalcommons.usu.edu/etd Part of the Biochemistry Commons Recommended Citation Smith, Allen H., "An Enzyme-Linked Immunosorbent Assay (ELISA) for Pantothenate" (1981). All Graduate Theses and Dissertations. 5295. https://digitalcommons.usu.edu/etd/5295 This Thesis is brought to you for free and open access by the Graduate Studies at DigitalCommons@USU. It has been accepted for inclusion in All Graduate Theses and Dissertations by an authorized administrator of DigitalCommons@USU. For more information, please contact [email protected]. AN ENZYME- LINKED ThltviUNOSORBE!'IT ASSAY (ELISA) FOR PANTOTHENATE by Allen H. Smith A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Biochemistry UTAH STATE UNIVERSITY Logan, Utah 1981 ii ACKNOWLEDGEMENTS To Dr. R. G. Hansen, to Dr. B. W. Wyse, to Carl Wittwer, to Jack Brown, to Jan Pearson, to Nedra Christensen, to all those who have made this experience one of tremendous growth, I express my thanks. I express appreciation to the United States Department of Agriculture, under Grant #5901-0410-9-0288-0 with Utah State University, for financial support. Finally, I express thanks to my parents, who have come to realize that graduate school is also a part of life. Allen H. Smith "iii TABLE OF CONTENTS Page ACKNOWLEDGEMENTS ii LIST OF TABLES . vi LIST OF FIGURES. vii · ABSTRACT .. ix INTRODUCTION 1 REVIEW OF LITERATURE 4 Pantothenate Assays .
  • Allergy Skin and Challenge Testing

    Allergy Skin and Challenge Testing

    Corporate Medical Policy Allergy Skin and Challenge Testing File Name: allergy_skin_and_challenge_testing Origination: 7/1979 Last CAP Review: 11/2020 Next CAP Review: 11/2021 Last Review: 11/2020 Description of Procedure or Service Management of the allergic patient may include identifying the offending agent by means of allergy testing. Allergy testing can be broadly grouped into in vivo and in vitro methodologies: • In vivo testing - includes allergy skin testing such as the scratch, puncture or prick test (epicutaneous), intradermal test (intracutaneous) and patch test, and food and bronchial challenges. • In vitro testing - includes various techniques to test the blood for the presence of specific IgE antibodies to a particular antigen. Once the agent is identified, treatment is provided by avoidance, medication or immunotherapy (allergy shots). Allergic or hypersensitivity disorders may be manifested by generalized systemic reactions as well as by localized reactions in any organ system of the body. The reactions may be acute, subacute, or chronic, immediate or delayed, and may be caused by numerous offending agents: pollen, molds, dust mites, animal dander, stinging insect venoms, foods, drugs, etc. This policy only addresses in vivo (skin and challenge) testing; for vitro testing, see policy titled, Allergen Testing. Related Policies: Allergy Immunotherapy Desensitization Allergen Testing AHS – G2031 Maximum Units of Service Idi ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for Allergy skin and challenge testing when it is determined to be medically necessary because the medical criteria and guidelines shown below are met.
  • Guidance and Protocol for the Serological Diagnosis of Human Infection with Bordetella Pertussis

    Guidance and Protocol for the Serological Diagnosis of Human Infection with Bordetella Pertussis

    TECHNICAL DOCUMENT Guidance and protocol for the serological diagnosis of human infection with Bordetella pertussis As part of the EUpert-Labnet surveillance network www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Guidance and protocol for the serological diagnosis of human infection with Bordetella pertussis As part of the EUpert-Labnet surveillance network This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Adoracion Navarro Torne, and produced by the members of the European Bordetella expert group ‘EUpert-Labnet’ as part of the project contract: Coordination of activities for laboratory surveillance of whooping cough in Member States and EEA countries (OJ/26/05/2011-PROC/2011/037) Authors Marion Riffelmann, HELIOS Kinikum Krefeld, Germany; Carl Heinz Wirsing von König, HELIOS Kinikum Krefeld, Germany; Dorothy Xing, National Institute for Biological Standards and Control (NIBSC), Health Protection Agency, Potters Bar, United Kingdom; Qiushui He, National Institute for Health and Welfare (THL), Turku, Finland. This protocol is intended to serve as a starting point for laboratories aiming at introducing ELISA serology for diagnosis of human Bordetella pertussis infections. Comments, requests or questions can be addressed to the authors. Version 1.0, October 2012 Disclaimer: this technical guidance is based on the latest available published data on diagnostic test performance at the time of writing. ECDC does not endorse any particular commercial product or instrument. Suggested citation:
  • UBI® SARS-Cov-2 ELISA INSTRUCTIONS for USE

    UBI® SARS-Cov-2 ELISA INSTRUCTIONS for USE

    UBI® SARS-CoV-2 ELISA INSTRUCTIONS FOR USE FOR IN VITRO DIAGNOSTIC USE ONLY FOR EMERGENCY USE AUTHORIZATION ONLY FOR PRESCRIPTION USE ONLY INTENDED USE The UBI® SARS-CoV-2 ELISA is an Enzyme-Linked Immunosorbent Assay (ELISA) intended for qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (sodium heparin or dipotassium (K2) EDTA). The UBI® SARS-CoV-2 ELISA is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The UBI® SARS-CoV-2 ELISA should not be used to diagnose or exclude acute SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, that meet requirements to perform high complexity testing. Results are for the detection of IgG SARS CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. The sensitivity of the UBI® SARS-CoV-2 ELISA early after infection is unknown. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.
  • FOR REFERENCE USE ONLY: DO NOT USE in Place of Package Inserts Provided with Each Product

    FOR REFERENCE USE ONLY: DO NOT USE in Place of Package Inserts Provided with Each Product

    [US] • Isotonic saline solution Coombscell-E IgG-coated Red Blood Cells for the control of the antiglobulin Coombscell-E is a single vial of group 0 red blood cells sensitized with human test monoclonal IgG antibodies (specificity anti-D). • Reagent Red Blood Cells: Biotest: Biotestcell® 1 & 2 [REF] 816014100, FOR IN-VITRO DIAGNOSTIC USE ® Biotestcell® 3 [REF] 816085100, Biotestcell -I 8 [REF] 816020100, For tube test ® Biotestcell -I 11 [REF] 816021100 Package size • Donor or patient red blood cells [REF] 816030100 [VOL] 10 mL Coombscell-E • MLB 2 (Modified LISS Biotest) [REF] 8065200100 • Anti-Human Globulin Anti-IgG [REF] 804175100 • Anti-Human Globulin Anti-IgG, -C3d Polyspecific [REF] 804115100 Intended Use Coombscell-E Red Blood Cells are used for • Glass tubes 10 x 75mm or 12 x 75mm • in-house quality control (reactivity control of Anti-Human-Globulin) • Serological centrifuge • to control the technique of antiglobulin-test with negative results • Interval Timer to verify the negative results of the IAT (Indirect Antiglobulin Test) and DAT • Markers (Direct Antiglobulin Test) • Optical aid (optional). The use of an optical aid for agglutination reading must be vaildated by the user. Summary Moreschi first described the use of Anti-Human Globulin in 19081. Coombs Test procedure rediscovered the test in 1945.2,3 By injecting rabbits with human IgG, they A. Tube test were able to produce a protein (Anti-IgG) that reacted with incomplete antibodies (IgG). Most “incomplete” antibodies (IgG) fail to agglutinate red Verification of negative result in antiglobulin test blood cells suspended in saline.4 Most clinically significant antibodies in red 1.
  • Switching from RIA to ELISA

    Switching from RIA to ELISA

    Switching from RIA to ELISA Being able to quantify biomarkers in a complex sample such as serum, cell culture media or even urine is of the utmost importance in biomarker research. Immunoassays that utilize highly specific the possibility of it measuring proglucagon-derived antibodies to detect biomarkers and analyze their peptides other than glucagon cannot be ruled out. concentration in such samples have been around An independent study has assessed the Mercodia since 1959 when Yalow and Berson first used sandwich ELISA and found it to be the most radiolabeled insulin to assess the concentration reliable assay for measuring glucagon3. of insulin in humans1. This radioimmunoassay (RIA) was followed by a new technique in 1971 when Engvall and Perlman developed an assay Pros and Cons where antigens immobilized on a microplate well are incubated with the sample and the Both ELISA and RIA can be used to measure concentration of the biomarker of interest glucagon, but the latter format is often based quantified using an enzyme-linked on a polyclonal antibody and may thus show anti-immunoglobulin antibody2. This method cross-reactivities to substances other than the is called enzyme-linked immunosorbent test analyte, such as hemoglobin and bilirubin. assay (ELISA). A sandwich ELISA, on the other hand, is based on two antibodies, which ensures high specificity for Since then, RIAs and ELISAs have been used the analyte. Mercodia ELISA assays are all based extensively to detect and quantify biomarkers. on monoclonal antibodies, so reproducibility There are, however, differences between the two between lots is assured. technologies that should be considered when comparing the two types and selecting an assay In addition, ELISA’s enzyme-based detection format.
  • Enzyme Immunoassay and Enzyme-Linked Immunosorbent Assay Stephanie D

    Enzyme Immunoassay and Enzyme-Linked Immunosorbent Assay Stephanie D

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector RESEARCH TECHNIQUES MADE SIMPLE Enzyme Immunoassay and Enzyme-Linked Immunosorbent Assay Stephanie D. Gan1 and Kruti R. Patel2 Journal of Investigative Dermatology (2013) 133, e12. doi:10.1038/jid.2013.287 INTRODUCTION Enzyme immunoassay (EIA) and enzyme-linked immunosor- WHAT ENZYME-LINKED bent assay (ELISA) are both widely used as diagnostic tools in IMMUNOSORBENT ASSAY (ELISA) DOES medicine and as quality control measures in various industries; • ELISA is a biochemical assay that uses antibodies they are also used as analytical tools in biomedical research and an enzyme-mediated color change to detect for the detection and quantification of specific antigens or anti- the presence of either antigen (proteins, peptides, bodies in a given sample. These two procedures share similar hormones, etc.) or antibody in a given sample. basic principles and are derived from the radioimmunoassay (RIA). RIA was first described by Berson and Yalow (Yalow and • Both “indirect” and “sandwich” ELISAs allow Berson, 1960), for which Yalow was awarded the Nobel Prize detection of antigen or antibody at very low in 1977, to measure endogenous plasma insulin. RIA was then concentrations. developed into a novel technique to detect and measure bio- • The competitive method detects compositional logical molecules present in very small quantities, paving the differences in complex antigen mixtures with way for the analysis and detection of countless other biologi- high sensitivity, even when the specific detecting cal molecules, including hormones, peptides, and proteins. antibody is present in relatively small amounts.
  • (ELISA) for the Detection of Anti-Double-Stranded DNA Igg

    (ELISA) for the Detection of Anti-Double-Stranded DNA Igg

    ORIGINAL ARTICLE J Bras Patol Med Lab. 2019; 55(2): 160-169. A quantitative enzyme-linked immunosorbent assay (ELISA) for the detection of anti-double-stranded DNA IgG antibodies 10.5935/1676-2444.20190018 Reação imunoenzimática (ELISA) quantitativa para detecção de anticorpos IgG anti-DNA de dupla hélice Elisângela O. Cavalcante; Lisandra A. Suzuki; Claudio Lucio Rossi Universidade Estadual de Campinas (Unicamp), Campinas, São Paulo, Brazil. ABSTRACT Introduction: The detection of anti-double-stranded (ds) deoxyribonucleic acid (DNA) antibodies is one of the classification criteria for diagnosing systemic lupus erythematosus (SLE). Objective: To describe a quantitative enzyme-linked immunosorbent assay (ELISA) for detecting anti-dsDNA immunoglobulin class G (IgG) antibodies. Methods: The performance of ELISA was evaluated using the Crithidia luciliae indirect immunofluorescence test (CLIFT) as a reference. Anti-dsDNA IgG antibodies were screened by ELISA and CLIFT in serum samples from 127 patients with SLE, 56 patients with other diseases and 37 healthy persons. The Cochran Q test was used to compare the sensitivity and specificity of the reactions, with differences among the results being considered significant when p ≤ 0.05. Results: ELISA had a sensitivity of 92.9% and a specificity of 94.6%, whereas the sensitivity and specificity of CLIFT were 85.8% and 100%, respectively. ELISA was significantly more sensitive than CLIFT (p = 0.0027), whereas CLIFT was significantly more specific than ELISA (p = 0.0253). Conclusion: ELISA showed excellent results in terms of sensitivity and specificity, with a potential use in research and routine diagnostics. Key words: systemic lupus erythematosus; antinuclear antibodies; enzyme-linked immunosorbent assay; indirect fluorescent antibody technique.
  • Enzyme Linked Immunosorbent Assay (ELISA) and Immunoprecipitation

    Enzyme Linked Immunosorbent Assay (ELISA) and Immunoprecipitation

    224 Gut 1994; 35:224-230 Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell Gut: first published as 10.1136/gut.35.2.224 on 1 February 1994. Downloaded from antibody using a mucin producing cell line in patients with inflammatory bowel disease T Hibi, M Ohara, K Kobayashi, W R Brown, K Toda, H Takaishi, Y Hosoda, A Hayashi, Y Iwao, M Watanabe, S Aiso, Y Kawai, M Tsuchiya Abstract epithelial cells in the colon and mediates specific Circulating anti-goblet cell antibody and its cytotoxicity to colonic epithelial cells.>" Except corresponding antigen in patients with inflam- for a 40 kD colitis colon associated antigen matory bowel disease were investigated. Anti- described by Das et al,'21'4 no other colon specific goblet cell antibody in the serum was examined antigens have been clarified yet. We have by immunocytochemistry and enzyme linked reported the high incidence of anti-colon anti- immunosorbent assay (ELISA), using a body, which reacts with the surface of isolated colonic cancer cell line, HT29-18-N2, which rat colonic epithelial cells and the presence of differentiates into intestinal goblet cells. The antibody dependent cell mediated cytotoxicity frequencies of anti-goblet cell antibody activity in the serum samples from patients with detected by immunocytochemistry were 14 in ulcerative colitis.'0 48 patients with ulcerative colitis (29%) and The other autoantibodies, anti-neutrophil five in 15 patients with Crohn's disease (33%). cytoplasmic antibodies (ANCA), have been By ELISA, the frequencies of anti-goblet cell recently found in inflammatory bowel disease.'5 antibody were 38% in ulcerative colitis and ANCA were present in most patients with 33% in Crohn's disease.